CoChat
Cited by 234

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

Open access
Hong, Xin, Roh, Whijae, Sullivan, Ryan J., Wong, Keith H.K., Wittner, Ben S., Guo, Hongshan, Dubash, Taronish D., Sade-Feldman, Moshe, Wesley, Benjamin, Horwitz, Elad, Boland, Genevieve M., Marvin, Dieuwke L., Bonesteel, Todd, Lu, Chenyue, Aguet, François, Burr, Risa, Freeman, Samuel S., Parida, Laxmi, Calhoun, Katherine, Jewett, Michelle K., Nieman, Linda T., Hacohen, Nir, Näär, Anders M., Ting, David T., Toner, Mehmet, Stott, Shannon L., Getz, Gad, Maheswaran, Shyamala, Haber, Daniel A. · 2021 · Cancer Discovery

Abstract

Circulating tumor cells (CTC) are shed by cancer into the bloodstream, where a viable subset overcomes oxidative stress to initiate metastasis. We show that single CTCs from patients with melanoma coordinately upregulate lipogenesis and iron homeostasis pathways. These are correlated with both intrinsic and acquired resistance to BRAF inhibitors across clonal cultures of BRAF-mutant CTCs. The lipogenesis regulator SREBP2 directly induces transcription of the iron carrier Transferrin (TF), reducing intracellular iron pools, reactive oxygen species, and lipid peroxidation, thereby conferring resistance to inducers of ferroptosis. Knockdown of endogenous TF impairs tumor formation by melanoma CTCs, and their tumorigenic defects are partially rescued by the lipophilic antioxidants ferrostatin-1 and vitamin E. In a prospective melanoma cohort, presence of CTCs with high lipogenic and iron metabolic RNA signatures is correlated with adverse clinical outcome, irrespective of treatment regimen. Thus, SREBP2-driven iron homeostatic pathways contribute to cancer progression, drug resistance, and metastasis. Significance: Through single-cell analysis of primary and cultured melanoma CTCs, we have uncovered intrinsic cancer cell heterogeneity within lipogenic and iron homeostatic pathways that modulates resistance to BRAF inhibitors and to ferroptosis inducers. Activation of these pathways within CTCs is correlated with adverse clinical outcome, pointing to therapeutic opportunities. This article is highlighted in the In This Issue feature, p. 521

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-19-1500

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 234

Metadata

Authors
Hong, X., Roh, W., Sullivan, R. J., Wong, K. H. K., Wittner, B. S., Guo, H., Dubash, T. D., Sade-Feldman, M., Wesley, B., Horwitz, E., Boland, G. M., Marvin, D. L., Bonesteel, T., Lu, C., Aguet, F., Burr, R., Freeman, S. S., Parida, L., Calhoun, K., Jewett, M. K., Nieman, L. T., Hacohen, N., Näär, A. M., Ting, D. T., Toner, M., Stott, S. L., Getz, G., Maheswaran, S., & Haber, D. A.
Venue
Cancer Discovery
Published
2021-03-01
Volume
11
Issue
3
Pages
678-695
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3103828236
Cited by
234
References
30
FWCI
12.81
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis. https://app.cochat.ai/papers/10.1158/2159-8290.cd-19-1500
The paper
Hong, X., Roh, W., Sullivan, R. J., Wong, K. H. K., Wittner, B. S., Guo, H., Dubash, T. D., Sade-Feldman, M., Wesley, B., Horwitz, E., Boland, G. M., Marvin, D. L., Bonesteel, T., Lu, C., Aguet, F., Burr, R., Freeman, S. S., Parida, L., Calhoun, K., . . . Haber, D. A. (2021). The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-19-1500

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.